Biotage AB Valuation
| BIOT Stock | SEK 103.50 2.00 1.90% |
At this time, the firm appears to be overvalued. Biotage AB shows a prevailing Real Value of kr99.51 per share. The current price of the firm is kr103.5. Our model approximates the value of Biotage AB from analyzing the firm fundamentals such as Current Valuation of 12.84 B, return on equity of 0.18, and Profit Margin of 0.16 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Biotage AB's price fluctuation is very steady at this time. Calculation of the real value of Biotage AB is based on 3 months time horizon. Increasing Biotage AB's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Biotage AB's intrinsic value may or may not be the same as its current market price of 103.50, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 103.5 | Real 99.51 | Hype 105.5 | Naive 122.04 |
The intrinsic value of Biotage AB's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biotage AB's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biotage AB helps investors to forecast how Biotage stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biotage AB more accurately as focusing exclusively on Biotage AB's fundamentals will not take into account other important factors: Biotage AB Total Value Analysis
Biotage AB is currently anticipated to have takeover price of 12.84 B with market capitalization of 10.45 B, debt of 180 M, and cash on hands of 311 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Biotage AB fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
12.84 B | 10.45 B | 180 M | 311 M |
Biotage AB Investor Information
About 65.0% of the company shares are held by institutions such as insurance companies. The company last dividend was issued on the 29th of April 2022. Biotage AB had 209:202 split on the 27th of October 2005. Based on the measurements of operating efficiency obtained from Biotage AB's historical financial statements, Biotage AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.Biotage AB Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biotage AB has an asset utilization ratio of 61.85 percent. This implies that the Company is making kr0.62 for each dollar of assets. An increasing asset utilization means that Biotage AB is more efficient with each dollar of assets it utilizes for everyday operations.Biotage AB Ownership Allocation
Biotage AB holds a total of 65.98 Million outstanding shares. Over half of Biotage AB's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulations than regular investors in Biotage AB. Please watch out for any change in the institutional holdings of Biotage AB as this could mean something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Biotage AB Profitability Analysis
The company reported the revenue of 1.23 B. Net Income was 269 M with profit before overhead, payroll, taxes, and interest of 755 M.About Biotage AB Valuation
The stock valuation mechanism determines Biotage AB's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Biotage AB based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biotage AB. We calculate exposure to Biotage AB's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biotage AB's related companies.Biotage AB , a life science company, provides solutions, knowledge, and experience in the areas of organic and analytical chemistry, as well as for industrial applications in the United States, Europe, Japan, China, and internationally. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, and academic institutions and commercial, hospitalbio-analytical, and forensic laboratories, as well as laboratories within food and environmental analysis. Biotage AB operates under Medical Instruments Supplies classification in Sweden and is traded on Stockholm Stock Exchange. It employs 438 people.
8 Steps to conduct Biotage AB's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Biotage AB's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Biotage AB's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Biotage AB's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Biotage AB's revenue streams: Identify Biotage AB's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Biotage AB's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Biotage AB's growth potential: Evaluate Biotage AB's management, business model, and growth potential.
- Determine Biotage AB's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Biotage AB's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Biotage Stock Analysis
When running Biotage AB's price analysis, check to measure Biotage AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotage AB is operating at the current time. Most of Biotage AB's value examination focuses on studying past and present price action to predict the probability of Biotage AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotage AB's price. Additionally, you may evaluate how the addition of Biotage AB to your portfolios can decrease your overall portfolio volatility.